S-18886 Servier

Stavros K Kakkos1, Andrew N Nicolaides

  • 1Irvine Laboratory for Cardiovascular Investigation and Research, Department of Vascular Surgery, Faculty of Medicine, Imperial College of Science, Technology and Medicine, 10th Floor QEQM Wing, St Mary's Hospital, London, W2 1NY, UK. s.kakkos@ic.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed
Summary

S-18886 is a long-acting thromboxane A2 receptor antagonist being developed for cardiovascular diseases. Clinical trials in coronary artery disease patients were underway by 2001.